mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-13. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
In late June 2019, Pritzker signed the bipartisan capital bill named Rebuild Illinois, worth $45 billion to be spent in six years and estimated to create 540,000 jobs. It was the first capital-spending bill in Illinois in 10 years. The plan includes $33.2 billion for transportation projects, including $25 billion for road upgrades, with local governments deciding which roads they want to prioritize; $3.5 billion for public and private schools and universities; $1 billion for environmental protection; $420 million for expanding broadband Internet service to rural Illinois; $465 million for health care and human services facilities; and $1.8 billion for libraries, museums, and minority-owned businesses. Financing for this plan will come from multiple sources. The gas tax was set to match inflation since the last gas-tax increase in 1990, increasing from 19 cents per gallon to 38 cents; the special fuel tax on diesel, liquefied natural gas, and propane increased to 7.5 cents per gallon. Fuel taxes will be indexed to inflation. Vehicle registration fees increased by $50. The state's bonding authority will increase from $22.6 billion to $60.8 billion. Newly authorized casinos are expected to create thousands of jobs and deliver hundreds of millions of dollars in tax revenue for construction projects. Cook County municipalities may raise their own gas taxes by up to three cents per gallon, though Chicago mayor Lori Lightfoot said she opposed raising the gas tax in her city and increasing Chicago Transit Authority fares.
Major Fishback's courageous letter shed light on the atrocities that were being committed—shamefully—in the name of our nation. ... After reports emerged from horrific abuses at Abu Ghraib in Iraq, I tried for a year and a half to pass legislation to make it clear that cruel, inhuman, and degrading treatment of detainees was illegal. Two military heroes, my former colleague Senator John McCain and Major Fishback, turned the tide in this effort.
The initial effects of exposure were coughing, severe eye irritation, a feeling of suffocation, burning in the respiratory tract, blepharospasm, breathlessness, stomach pains, and vomiting. People alerted by these symptoms fled from the plant. Those who ran inhaled more than those in vehicles. Owing to their height, children and other residents of shorter stature inhaled higher concentrations, as methyl isocyanate gas is approximately twice as dense as air and in an open environment has a tendency to fall toward the ground. Thousands of people had died by the following morning. Primary causes of deaths were choking, reflexogenic circulatory collapse, and pulmonary oedema. Findings during autopsies revealed changes not only in the lungs but also cerebral oedema, tubular necrosis of the kidneys, fatty degeneration of the liver, and necrotising enteritis. The individuals who did not die suffered from cancer, blindness, loss of livelihood, and financial strain.
== Overdose == The median lethal dose of THC in humans is not fully known as there is conflicting evidence. A 1972 study gave up to 90 mg/kg of THC to dogs and monkeys without any lethal effects. Some rats died within 72 hours after a dose of up to 36 mg/kg. A 2014 case study based on the toxicology reports and relative testimony in two separate cases gave the median lethal dose in humans at 30 mg/kg (2.1 grams THC for a person who weighs 70 kg; 154 lb; 11 stone), observing cardiovascular death in the one otherwise healthy subject of the two cases studied. A different 1972 study gave the median lethal dose for intravenous THC in mice and rats at 30–40 mg/kg. A 2020 fact sheet published by the US Drug Enforcement Administration stated that "no deaths from overdose of marijuana have been reported."
High entry barriers because of demanding technology: the construction of a large-scale plant for the production of biopharmaceuticals by cell culture fermentation costs around $500 million and takes four to six years. As the specifications of the plant and process types for biopharmaceuticals differ substantially from traditional chemical synthesis, they cannot be produced in conventional multipurpose fine chemical plants. High financial exposure, due to high capital intensity (as massive investments are needed at a time when chances of success are still very low) and risk of batch failures (contamination). Unlike the biopharmaceutical start-ups, the emerging big biopharmaceutical companies are adopting the same opportunistic outsourcing policy as larger pharmaceutical companies. Thus, Amgen, Biogen Idec, Eli Lilly, Johnson & Johnson (J&J), Medimmune, Novartis, Roche-Genentech and Pfizer are investing heavily in in-house manufacturing capacity. With three plants in the US, two in Japan and one each in Germany and Switzerland, Roche has the largest production capacity. New developments in expression systems for mammalian and plant cell technology could reduce capacity requirements substantially: the titer in large-scale mammalian production, 2–3 grams/liter, is expected to double to 5–7 by 2015 go up to 10 by 2020. Furthermore, the widespread application of "single-use disposable bioprocessing technology" advantageously substitutes for stainless steel production trains, at least for short production campaigns.
Sources: en.wikipedia.org
== Side effects == The most common side effects include constipation, nausea and drowsiness. Others include coughing up blood from the lungs, skin rashes, dizziness, sedation, shortness of breath, hypersensitivity reaction, fainting (syncope or near syncope), confusion, loss of short-term memory, changes in blood, allergic reactions, euphoria, dysphoria, abdominal pain, itchiness, easy bruising, bleeding gums, vivid dreams, dry mouth and addiction. Genetic differences between people cause differing rates of metabolism of codeine to morphine. In about 5 percent of people this may happen particularly fast, causing morphine to be passed through breast milk in amounts that may cause fatal respiratory depression in a breastfed baby.
=== Plant screening program === In 1955, the NCI in the United States set up the Cancer Chemotherapy National Service Center (CCNSC) to act as a public screening center for anticancer activity in compounds submitted by external institutions and companies. Although the majority of compounds screened were of synthetic origin, one chemist, Jonathan Hartwell, who was employed there from 1958 onwards, had experience with natural product derived compounds, and began a plant screening operation. After some years of informal arrangements, in July 1960, the NCI commissioned the United States Department of Agriculture (USDA) botanists to collect samples from about 1,000 plant species per year. On 21 August 1962, one of those botanists, Arthur S. Barclay, collected bark from a single Pacific yew tree in a forest north of the town of Packwood, Washington, as part of a four-month trip to collect material from over 200 different species. The material was then processed by a number of specialist CCNSC subcontractors, and one of the tree's samples was found to be cytotoxic in a cellular assay on 22 May 1964. Accordingly, in late 1964 or early 1965, the fractionation and isolation laboratory run by Monroe E. Wall in Research Triangle Park, North Carolina, began work on fresh Taxus samples, isolating the active ingredient in September 1966 and announcing their findings at an April 1967 American Chemical Society meeting in Miami Beach. They named the pure compound taxol in June 1967. Wall and his colleague Wani published their results, including the chemical structure, in 1971.
=== Electricity demand and grid capacity === The proliferation of AI has driven a surge in data centre construction and power requirements. According to the National Energy System Operator (NESO), UK data centres consumed 5.0 TWh of electricity in 2023, equivalent to 2% of total UK electricity demand and 7% of commercial sector consumption. However, Oxford Economics forecasts that total demand could grow more than fivefold by 2030, reaching 26.2 TWh, which would represent 8.8% of total UK electricity demand and 30.4% of commercial electricity consumption. This rapid growth has created friction with the UK's net zero targets. In February 2026, the Environmental Audit Committee raised concerns that the government had not adequately factored data centre energy consumption into the draft Seventh Carbon Budget. The energy regulator Ofgem disclosed that developers of new data centres had enquired about grid connections that would require more energy at peak times than the whole of Britain consumes on some days.
The violin pattern is not a definitive identifier, as other spiders can have similar markings (e.g. cellar spiders and pirate spiders). Instead, while most spiders have eight eyes, recluse spiders have six eyes arranged in pairs (dyads) with one median pair and two lateral pairs. Only a few other spiders have three pairs of eyes arranged in this way (e.g., scytodids). Recluses have no obvious coloration patterns on the abdomen or legs, and the legs lack spines. The violin marking can vary in intensity depending on the age of the brown recluse spider, with mature spiders typically having dark violin shapes.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.